Mubadala Bio Launches Advanced Cancer Treatment Facility: Pioneering Oncology Medicines

Mubadala Bio, the UAE's national pharmaceutical manufacturer, opened a new high-potency drug facility and launched three cancer medications. Two of these drugs are being produced locally for the first time as generic alternatives, marking a significant step in the UAE's push for pharmaceutical independence.

The new facility, operated by subsidiary BioVenture Healthcare, was designed specifically to handle complex, high-potency medications including cancer drugs and hormones. It meets international safety and quality standards, positioning the UAE to produce critical medications that were previously imported.

The three cancer drugs now in production are Lenalidomide and Pomalidomide, both used to treat multiple myeloma (a type of blood cancer), and Sunitinib, which targets specific types of advanced cancer. Pomalidomide represents a particularly important milestone as it's the first time this medication has been manufactured locally in the UAE.

This move addresses a key vulnerability in healthcare supply chains. Cancer medications are often expensive and subject to global supply disruptions. By producing these drugs domestically, the UAE can better control costs and ensure consistent availability for patients who depend on these life-saving treatments.

The facility represents part of a broader strategy to build pharmaceutical self-sufficiency. Multiple myeloma affects thousands of patients across the Middle East, and these medications can cost tens of thousands of dollars per year when imported. Local production typically reduces costs significantly while improving supply reliability.

Dr. Bakhit Al Kathiri, CEO of UAE Investments at Mubadala and chairman of Mubadala Bio, said the launch adds important capabilities to the company's growing portfolio. The facility will benefit healthcare providers and patients by improving access to advanced treatments.

Dr. Essam Mohamed, CEO of Mubadala Bio, emphasized the company's commitment to strengthening the UAE's pharmaceutical production ecosystem. The investment in national capabilities ensures that patients have continuous access to essential cancer treatments.

The timing is strategic. Global pharmaceutical supply chains faced major disruptions during recent years, highlighting the risks of depending entirely on imports for critical medications. Countries worldwide are now prioritizing domestic pharmaceutical production, particularly for essential drugs like cancer treatments.

For investors and industry watchers, this represents the UAE's serious commitment to building a complete pharmaceutical value chain. The country already serves as a regional hub for pharmaceutical distribution, but local manufacturing adds another layer of economic value and strategic security.